<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39247972</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>e29862</StartPage><MedlinePgn>e29862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29862</ELocationID><Abstract><AbstractText>Limited research suggests that certain viruses reactivate in severe-acute-respiratory-syndrome-coronavirus 2 infection, contributing to the development of postacute sequelae of COVID-19 (PASC). We examined 1083 infected individuals from a population-based cohort, and assessed differences in plasma immunoglobulin (Ig)G and immunoglobulin A levels against Epstein-Barr virus (EBV), cytomegalovirus, varicella zoster virus (VZV), BK polyomavirus, KI polyomavirus, WU polyomavirus (WUPyV), respiratory syncytial virus, and Adv-36 according to the severity of previous COVID-19 and PASC history. Individuals who had experienced severe COVID-19 had higher antibody responses to latent viruses. Ever PASC, active persistent PASC, and PASC with neuropsychiatric symptoms were associated with higher immnoglobulin G to EBV early antigen-diffuse, VZV, and WUPyV even among individuals without previous severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karachaliou</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3014-0747</Identifier><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranzani</LastName><ForeName>Otavio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiologia y Salud P&#xfa;blica (CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iraola-Guzm&#xe1;n</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genomes for Life-GCAT Lab, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casta&#xf1;o-Vinyals</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiologia y Salud P&#xfa;blica (CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez</LastName><ForeName>Alfons</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#xf1;uls</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogu&#xe9;s</LastName><ForeName>Eva Alonso</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Banc de Sang i Teixits (BST), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Aymerich</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiologia y Salud P&#xfa;blica (CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Cid</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Genomes for Life-GCAT Lab, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doba&#xf1;o</LastName><ForeName>Carlota</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6751-4060</Identifier><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moncunill</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogevinas</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Epidemiologia y Salud P&#xfa;blica (CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>RYC 2020-029886 I/ AEI/10.13039/501100011033</Agency><Country/></Grant><Grant><Agency>Fundaci&#xf3; Privada Daniel Bravo Andreu</Agency><Country/></Grant><Grant><Agency>Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA)</Agency><Country/></Grant><Grant><Agency>END-VOC Project (Horizon 2021-2024)</Agency><Country/></Grant><Grant><Agency>Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 programme (CEX2018-000806-S)</Agency><Country/></Grant><Grant><Agency>Acci&#xf3;n de Dinamizaci&#xf3;n del ISCIII-MINECO</Agency><Country/></Grant><Grant><GrantID>ADE 10/00026</GrantID><Agency>Ministry of Health of the Generalitat of Catalunya</Agency><Country/></Grant><Grant><GrantID>SGR 01537</GrantID><Agency>Ag&#xe8;ncia de Gesti&#xf3; d'Ajuts Universitaris i de Recerca (AGAUR)</Agency><Country/></Grant><Grant><GrantID>PI18/01512</GrantID><Agency>Spanish National</Agency><Country/></Grant><Grant><GrantID>TED2021-130626B-I00</GrantID><Agency>Spanish National</Agency><Country/></Grant><Grant><GrantID>La MaratoTV3 167/C/2021</GrantID><Agency>Spanish National</Agency><Country/></Grant><Grant><GrantID>101046314</GrantID><Agency>European Union</Agency><Country/></Grant><Grant><Agency>MENARINI</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">herpesviruses</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">polyomaviruses</Keyword><Keyword MajorTopicYN="N">postacute sequelae of COVID&#x2010;19</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39247972</ArticleId><ArticleId IdType="doi">10.1002/jmv.29862</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>LONG COVID DEFINITION: A Chronic, Systemic Disease State With Profound Consequences. S.l. National Academies Press; 2024.</Citation></Reference><Reference><Citation>Kim JYH, Ragusa M, Tortosa F, et al. Viral reactivations and co&#x2010;infections in COVID&#x2010;19 patients: a systematic review. BMC Infect Dis. 2023;23(1):259.</Citation></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post&#x2212;COVID&#x2010;19 condition: a systematic review and meta&#x2010;analysis. JAMA Internal Medicine. 2023;183(6):566.</Citation></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB. Recover mechanistic pathways task force. viral persistence, reactivation, and mechanisms of long COVID. eLife. 2023;12:e86015.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146.</Citation></Reference><Reference><Citation>Ozonoff A, Jayavelu ND, Liu S, et al. Features of acute COVID&#x2010;19 associated with post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 phenotypes: results from the IMPACC study. Nat Commun. 2024;15(1):216.</Citation></Reference><Reference><Citation>Karachaliou M, Moncunill G, Espinosa A, et al. SARS&#x2010;CoV&#x2010;2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. BMC Med. 2022;20(1):347.</Citation></Reference><Reference><Citation>Karachaliou M, Moncunill G, Espinosa A, et al. Infection induced SARS&#x2010;CoV&#x2010;2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain. Sci Rep. 2021;11(1):21571.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post&#x2010;COVID&#x2010;19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2010;e107.</Citation></Reference><Reference><Citation>Bernal KDE, Whitehurst CB. Incidence of Epstein&#x2010;Barr virus reactivation is elevated in COVID&#x2010;19 patients. Virus Res. 2023;334:199157.</Citation></Reference><Reference><Citation>Hoeggerl AD, Nunhofer V, Lauth W, et al. Epstein&#x2010;Barr virus reactivation is not causative for post&#x2010;COVID&#x2010;19&#x2010;syndrome in individuals with asymptomatic or mild SARS&#x2010;CoV&#x2010;2 disease course. BMC Infect Dis. 2023;23(1):800.</Citation></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein&#x2010;Barr virus reactivation. Pathogens. 2021;10(6):763.</Citation></Reference><Reference><Citation>Peluso MJ, Deveau T&#x2010;M, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133(3):e163669.</Citation></Reference><Reference><Citation>De Paschale M. Serological diagnosis of Epstein&#x2010;Barr virus infection: problems and solutions. World J Virol. 2012;1(1):31.</Citation></Reference><Reference><Citation>Chen YC, Ho CH, Liu TH, et al. Long&#x2010;term risk of herpes zoster following COVID&#x2010;19: a retrospective cohort study of 2 442 686 patients. J Med Virol. 2023;95(4):e28745.</Citation></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139&#x2010;148.</Citation></Reference><Reference><Citation>Cervia&#x2010;Hasler C, Br&#xfc;ningk SC, Hoch T, et al. Persistent complement dysregulation with signs of thromboinflammation in active long covid. Science. 2024;383(6680):eadg7942.</Citation></Reference><Reference><Citation>Prezioso C, Moens U, Oliveto G, et al. KI and WU polyomavirus in respiratory samples of SARS&#x2010;CoV&#x2010;2 infected patients. Microorganisms. 2021;9(6):1259.</Citation></Reference><Reference><Citation>Bilbo SD, Schwarz JM. The immune system and developmental programming of brain and behavior. Front Neuroendocrinol. 2012;33(3):267&#x2010;286.</Citation></Reference><Reference><Citation>Randhawa PS, Gupta G, Vats A, Shapiro R, Viscidi RP. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol. 2006;13(9):1057&#x2010;1063.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>